,address1,address2,city,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,lastSplitFactor,lastSplitDate,enterpriseToRevenue,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationKey,totalCash,totalCashPerShare,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,grossProfits,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,Onoya-Kyobashi Building,1-4-10 Kyobashi Chuo-ku,Tokyo,104-0031,Japan,81 3 3241 0550,81 3 3241 0554,https://www.nanomrna.co.jp,Biotechnology,Healthcare,"NANO MRNA Co.,Ltd. researches, develops, produces, and sells pharmaceuticals using micelle nanoparticle technology primarily for the treatment of cancer in Japan. The company's pipeline products includes ENT103, an antibacterial eardrops for the treatment of otitis media; NC-6300 Epirubicin micelle that is in phase I clinical trials; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma and RUNX1 (mRNA) for osteoarthritis of the knee that are in preclinical stage. The company was formerly known as NanoCarrier Co., Ltd. and changed its name to NANO MRNA Co.,Ltd. in June 2023. NANO MRNA Co.,Ltd. was incorporated in 1996 and is headquartered in Tokyo, Japan.",17,"{'maxAge': 1, 'name': 'Dr. Shiro  Akinaga Ph.D.', 'title': 'Pres, CEO, CSO, MD of R&D Division and Director', 'exercisedValue': 0, 'unexercisedValue': 0}",86400,4,1.17,1.15,1.15,1.16,1.17,1.15,1.15,1.16,0.0,0.484984,50,50,2,5,5,1.16,1.21,22300,21000,84280384,1.07,1.9,0.41722962,1.1784,1.363,0.0,0.0,EUR,-3377357312,0.0,62474344,70381696,0.09078,0.03836,57.0,0.020350877,1680220800,1711843200,1688083200,-1310000000,-0.12,100:1,1395878400,-16.72,FRA,EQUITY,3NQ.F,3NQ.F,NANO MRNA CO. LTD.,"NANO MRNA Co.,Ltd.",1206082800,Europe/Berlin,CEST,7200000,1.16,none,4567000064,64.889,1108000000,12.302,12.824,202000000,27.714,2.882,160000000,-1087000064,0.78713,0.0,-6.1683197,JPY,
1,Onoya-Kyobashi Building,1-4-10 Kyobashi Chuo-ku,Tokyo,104-0031,Japan,81 3 3241 0550,81 3 3241 0554,https://www.nanomrna.co.jp,Biotechnology,Healthcare,"NANO MRNA Co.,Ltd. researches, develops, produces, and sells pharmaceuticals using micelle nanoparticle technology primarily for the treatment of cancer in Japan. The company's pipeline products includes ENT103, an antibacterial eardrops for the treatment of otitis media; NC-6300 Epirubicin micelle that is in phase I clinical trials; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma and RUNX1 (mRNA) for osteoarthritis of the knee that are in preclinical stage. The company was formerly known as NanoCarrier Co., Ltd. and changed its name to NANO MRNA Co.,Ltd. in June 2023. NANO MRNA Co.,Ltd. was incorporated in 1996 and is headquartered in Tokyo, Japan.",17,"{'maxAge': 1, 'name': 'Mr. Tetsuhito  Matsuyama', 'age': 60, 'title': 'Managing Director', 'yearBorn': 1962, 'exercisedValue': 0, 'unexercisedValue': 0}",86400,4,1.17,1.15,1.15,1.16,1.17,1.15,1.15,1.16,0.0,0.484984,50,50,2,5,5,1.16,1.21,22300,21000,84280384,1.07,1.9,0.41722962,1.1784,1.363,0.0,0.0,EUR,-3377357312,0.0,62474344,70381696,0.09078,0.03836,57.0,0.020350877,1680220800,1711843200,1688083200,-1310000000,-0.12,100:1,1395878400,-16.72,FRA,EQUITY,3NQ.F,3NQ.F,NANO MRNA CO. LTD.,"NANO MRNA Co.,Ltd.",1206082800,Europe/Berlin,CEST,7200000,1.16,none,4567000064,64.889,1108000000,12.302,12.824,202000000,27.714,2.882,160000000,-1087000064,0.78713,0.0,-6.1683197,JPY,
2,Onoya-Kyobashi Building,1-4-10 Kyobashi Chuo-ku,Tokyo,104-0031,Japan,81 3 3241 0550,81 3 3241 0554,https://www.nanomrna.co.jp,Biotechnology,Healthcare,"NANO MRNA Co.,Ltd. researches, develops, produces, and sells pharmaceuticals using micelle nanoparticle technology primarily for the treatment of cancer in Japan. The company's pipeline products includes ENT103, an antibacterial eardrops for the treatment of otitis media; NC-6300 Epirubicin micelle that is in phase I clinical trials; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma and RUNX1 (mRNA) for osteoarthritis of the knee that are in preclinical stage. The company was formerly known as NanoCarrier Co., Ltd. and changed its name to NANO MRNA Co.,Ltd. in June 2023. NANO MRNA Co.,Ltd. was incorporated in 1996 and is headquartered in Tokyo, Japan.",17,"{'maxAge': 1, 'name': 'Mr. Koji  Fujimoto', 'age': 50, 'title': 'MD of Corp. Division & Director', 'yearBorn': 1972, 'exercisedValue': 0, 'unexercisedValue': 0}",86400,4,1.17,1.15,1.15,1.16,1.17,1.15,1.15,1.16,0.0,0.484984,50,50,2,5,5,1.16,1.21,22300,21000,84280384,1.07,1.9,0.41722962,1.1784,1.363,0.0,0.0,EUR,-3377357312,0.0,62474344,70381696,0.09078,0.03836,57.0,0.020350877,1680220800,1711843200,1688083200,-1310000000,-0.12,100:1,1395878400,-16.72,FRA,EQUITY,3NQ.F,3NQ.F,NANO MRNA CO. LTD.,"NANO MRNA Co.,Ltd.",1206082800,Europe/Berlin,CEST,7200000,1.16,none,4567000064,64.889,1108000000,12.302,12.824,202000000,27.714,2.882,160000000,-1087000064,0.78713,0.0,-6.1683197,JPY,
